axp107-11
Childhood Lymphoma
University of VirginiaPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Childhood Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Actuate Therapeutics Inc. | Phase 1 | CC |
iopofosine (¹³¹I) Cellectar Biosciences, Inc. | Phase 1 | CC |
Irinotecan Actuate Therapeutics Inc. | Phase 1 | CC |
Hycamtin Actuate Therapeutics Inc. | Phase 1 | CC |
Decitabine Children's Hospital Medical Center, Cincinnati | Early Phase 1 | CC |
Pembrolizumab Children's Hospital Medical Center, Cincinnati | Early Phase 1 | CC |
ELRAGLUSIB Actuate Therapeutics Inc. | Phase 1 | CC |
Same molecule, other indications
axp107-11 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →